EGFR and squamous cell carcinoma of penis: A single-center phase II trial of toripalimab (anti-PD-1), nimotuzumab (anti-EGFR), and taxane-based chemotherapy in locally advanced PSCC (TNT regimen) reported an ORR above 80% and encouraging 2-year PFS and OS, supporting the concept of multi-agent biochemotherapy in the neoadjuvant setting [238].